清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

ERN EURO-NMD expert opinion on management of new biologic therapies in myasthenia gravis

医学 报销 重症肌无力 重症监护医学 临床试验 专家意见 生活质量(医疗保健) 立场文件 疾病 梅德林 弱点 代理(哲学) 限制 循证医学 医疗保健 疾病管理 胸腺切除术 质量(理念) 替代医学 临床实习 物理疗法 随机对照试验 神经肌肉疾病 系统回顾 最佳实践 基础(证据) 循证实践 食品药品监督管理局
作者
Marta Cheli,John Vissing,Sithara Ramdas,Voháňka Stanislav,Maria Bonaria Uccheddu,Allard Lutgarde,Anthony Béhin,Elena Cortés‐Vicente,Anna Kostera‐Pruszczyk,Anna Rostedt Punga,Nils Erik Gilhus,Andreas Meisel,Lorenzo Maggi
出处
期刊:Brain [Oxford University Press]
卷期号:: awag407-
标识
DOI:10.1093/brain/awag407
摘要

Myasthenia Gravis is a potentially life-threatening autoimmune disease of the neuromuscular junction with fluctuating muscle weakness and fatigability. In recent years, the therapeutic landscape has been notably reshaped by the introduction of new therapies. These agents, primarily acting through complement inhibition or neonatal Fc-receptor blockade, have demonstrated significant efficacy and favorable safety profiles in randomized clinical trials and real-world settings. Their advent has refined clinical management, particularly in refractory patients, leading to meaningful improvements in patients' quality of life and future expectations. Meanwhile, in this evolving therapeutic landscape, new challenges and uncertainties in clinical decision-making have been raised, as new therapies are now part of the standard care in Myasthenia Gravis. Differences in regulatory agency approvals and reimbursement policies across Europe result in heterogeneous access to therapies, complicating treatment decisions and limiting shared real-world experiences. Consequently, clinicians face complex dilemmas regarding optimal patient selection, treatment choice, and long-term management strategies. To address these issues, a panel of experts, including adult and pediatric neurologists and patient representatives, within the framework of the European Reference Network for Neuromuscular Diseases convened to develop consensus-based positions. The aim of this work was to identify, explore, and discuss key challenges associated with the use of new therapies and to propose a practical approach to support clinicians in this rapidly evolving field. Given the variability in clinical approach, treatment availability and reimbursement policies across European healthcare systems, this position paper seeks to provide guidance that are adaptable across diverse settings. A literature review was conducted, focusing on pivotal clinical trials and real-world evidence. Eleven key topics were identified and discussed, and for each, consensus statements were developed and refined through a modified Delphi process: patient assessment from both clinician and patient perspectives; the role of autoantibodies and optimization of serological testing; selection of immunotherapies; definitions of treatment response and failure in the context of new therapies; strategies for switching between therapies; predictors of treatment response; management of concomitant therapies, including corticosteroids and conventional immunosuppressant; discontinuation strategies; their potential role as early-line therapies; their applicability in ocular MG; and future therapeutic perspectives, including ongoing clinical trials. In conclusion, new therapies represent a major advance in Myasthenia Gravis care but also introduce significant complexity. This expert position paper provides a framework to support clinicians in decision-making and highlights the need for harmonized guidelines and further research to optimize their use in routine practice.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
null的应助被科研通管家采纳,获得10
3秒前
高高仙人掌完成签到,获得积分10
7秒前
殷勤的半凡完成签到,获得积分10
9秒前
安详的老五完成签到,获得积分10
10秒前
火星上的笑寒完成签到,获得积分10
34秒前
ding的应助被amiee采纳,获得10
39秒前
含蓄的新柔完成签到,获得积分10
41秒前
dianeil发布了新的文献求助10
50秒前
1分钟前
amiee发布了新的文献求助10
1分钟前
somehgo的应助被betsydouglas14采纳,获得30
1分钟前
共享精神的应助被ping采纳,获得10
1分钟前
包容的初阳完成签到,获得积分10
1分钟前
1分钟前
激动的忆翠完成签到,获得积分10
1分钟前
风趣馒头完成签到,获得积分10
1分钟前
1分钟前
无私的碧玉完成签到,获得积分10
1分钟前
俭朴迎荷完成签到,获得积分10
1分钟前
1分钟前
n01W97的应助被科研通管家采纳,获得70
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
null的应助被科研通管家采纳,获得10
2分钟前
怕黑靖荷完成签到,获得积分10
2分钟前
专一的思菱完成签到,获得积分10
2分钟前
2分钟前
欢呼亦绿完成签到,获得积分10
2分钟前
ping发布了新的文献求助10
2分钟前
文静飞松完成签到,获得积分10
2分钟前
喜悦的紫雪完成签到,获得积分10
3分钟前
故意的白风完成签到,获得积分10
3分钟前
要减肥的菀完成签到,获得积分10
3分钟前
矢思然完成签到,获得积分10
3分钟前
蓝意完成签到,获得积分0
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
cocolinfly完成签到 ,获得积分10
4分钟前
null的应助被科研通管家采纳,获得10
4分钟前
Maestro_S的应助被科研通管家采纳,获得10
4分钟前
烂漫的诗蕊完成签到,获得积分10
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185411
求助须知:如何正确求助?哪些是违规求助? 9574140
关于积分的说明 21834375
捐赠科研通 7782865
什么是DOI,文献DOI怎么找? 3434552
关于科研通互助平台的介绍 2558842
邀请新用户注册赠送积分活动 2481280